Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 187 от 222

Набира участници Фаза 1/2

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

HER2-positive Advanced Solid Tumor

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Начало: 31.01.2022 Край: 01.10.2027 Възраст: от 18 г. Лечение

Australia, China, Puerto Rico +3 DualityBio Inc. NCT05150691

Набира участници Фаза 1/2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Diffuse Midline Glioma, H3 K27-Altered Metastatic Malignant Neoplasm in the Central Nervous System Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Diffuse Midline Glioma, H3 K27-Altered +6

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.

Начало: 28.01.2022 Край: 31.12.2026 Възраст: 12–21 г. Лечение

Australia, United States Children's Oncology Group NCT04870944

Набира участници

WithHolding Enteral Feeds Around Blood Transfusion (International)

Necrotizing Enterocolitis

The WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (\

Начало: 28.01.2022 Край: 31.03.2027 Възраст: до 30 г.

Canada, United Kingdom IWK Health Centre NCT05213806

Набира участници Фаза 2/3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

DLBCL Diffuse Large B-Cell Lymphoma

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR. With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B.

Начало: 14.01.2022 Край: 24.09.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +22 Merck Sharp & Dohme LLC NCT05139017

Набира участници Фаза 2

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Unresectable Gastrointestinal Stromal Tumor (GIST) Locally Advanced Gastrointestinal Stromal Tumor (GIST) Metastatic Gastrointestinal Stromal Tumor

This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease progression),sunitinib and regorafenib (either disease progression or intolerance) In the first arm, patients will be treated with imatinib + atezolizumab (experimental arm), whereas in the second arm, patients will be treated with imatinib alone (control arm). The comparison between this two arms will allow to compare whether or not atezolizumab and imatinib is efficient for disease control, in terms of Progression-Free Survival improvement.

Начало: 14.01.2022 Край: 01.10.2027 Възраст: от 18 г.

France Centre Leon Berard NCT05152472

Набира участници Фаза 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

AMD nAMD Wet Age-related Macular Degeneration wAMD +2

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.

Начало: 13.01.2022 Край: 01.11.2027 Възраст: 50–89 г.

Canada, France, Germany +7 AbbVie NCT05407636

Набира участници

Pancreatic Cancer Screening in a Population at High Risk

Pancreatic Ductal Adenocarcinoma Hereditary Diseases Pancreatitis, Chronic

Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".

Начало: 07.01.2022 Край: 06.01.2028 Възраст: от 18 г.

Czechia Masaryk Memorial Cancer Institute NCT06330441

Набира участници Фаза 3

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Type 2 Diabetes Mellitus Chronic Kidney Diseases

The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.

Начало: 05.01.2022 Край: 01.12.2029 Възраст: 30–80 г. Лечение

Australia, Canada, Mexico +4 Prokidney NCT05099770

Набира участници

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Refractory Angina

To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects with reversible myocardial ischemia in the distribution of the right coronary artery and who are deemed unsuitable for revascularization, subjects without documented obstructive coronary disease and abnormal coronary flow reserve (ANOCA), and subjects who cannot complete an exercise tolerance test due to lower limb amputation (above the ankle) or other physiologic condition with documented chronic mobility or balance issues that require the use of a walking aid.

Начало: 04.01.2022 Край: 01.01.2032 Възраст: от 18 г.

Canada, United Kingdom, United States Shockwave Medical, Inc. NCT05102019

Набира участници Фаза 1/2

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Locally Advanced Solid Tumor Metastatic Solid Tumor

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of zidesamtinib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors.

Начало: 04.01.2022 Край: 31.12.2028 Възраст: от 12 г. Лечение

Australia, Belgium, Canada +11 Nuvalent Inc. NCT05118789

Набира участници Фаза 1

PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study

NSCLC

Outcome for patients diagnosed with advanced lung cancer remains poor; alternative treatment options are urgently needed. Studies in other metastatic cancers indicate radiotherapy to the primary tumour can improve outcomes. The investigators postulate this will also be observed in lung cancer patients. The aim of this pilot study is to assess the safety and feasibility of stereotactic ablative radiotherapy (SABR) to the lung primary prior to standard of care (SoC) systemic therapy in advanced non-small cell lung cancer (NSCLC). Forty patients with advanced (Stage IV) NSCLC will be recruited across the five Peter Mac campuses. Patients will be randomised to receive SoC systemic therapy with or without radiotherapy to the lung primary. Radiotherapy will be delivered before cycle 3 of SoC systemic therapy. Biospecimens will be collected for future translational research. The primary outcome of the study (feasibility of the protocol) will be assessed by the ability to deliver radiotherapy to the lung cancer primary, whilst meeting dose constraints. The study will also 1) evaluate proportion of patients who are willing to be randomised; 2) describe toxicity during the follow up period in each arm; 3) describe progression free survival.

Начало: 03.01.2022 Край: 01.04.2025 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05222087

Набира участници

RibFix Blu Thoracic Fixation System Versus Non-surgical Treatment in Non-flail Chest Rib Fractures

Rib; Fracture

This is a prospective, multi-center, observational, cohort study involving skilled cardiothoracic surgeons who are experienced in implanting the treatment of non-flail chest rib fractures and the use of RibFix Blu Thoracic Fixation System.

Начало: 02.01.2022 Край: 30.12.2026 Възраст: от 18 г.

Australia, South Korea Zimmer Biomet NCT05146986

Набира участници

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

Hepatocellular Carcinoma HCC

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage. Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic. Currently no guideline offers an alternative surveillance tool for patients who have suboptimal surveillance ultrasounds.

Начало: 01.01.2022 Край: 01.03.2027 Възраст: 20–85 г. Скрининг

Australia, New Zealand Concord Repatriation General Hospital NCT04455932

Набира участници

Long Lasting Effect of Hyperbaric Oxygen Therapy on Cognitive Function in Traumatic Brain Injury Patients

TBI (Traumatic Brain Injury)

To evaluate the cognitive functions of patients who suffered brain injury due to traumatic head injury and were previously treated in a hyperbaric chamber between one and four years after the end of treatment.

Начало: 28.12.2021 Край: 01.01.2030 Възраст: от 18 г.

Israel Assaf-Harofeh Medical Center NCT07430150

Набира участници

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

Thymoma Malignant Recurrent

The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.

Начало: 28.12.2021 Край: 28.12.2032 Възраст: 18–75 г.

France Institut Curie NCT04731610

Набира участници Фаза 1/2

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Angelman Syndrome

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.

Начало: 22.12.2021 Край: 01.03.2029 Възраст: до 50 г. Лечение

Australia, France, Israel +3 Ionis Pharmaceuticals, Inc. NCT05127226

Набира участници Фаза 1

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Advanced Solid Tumors

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

Начало: 17.12.2021 Край: 25.02.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +18 Merck Sharp & Dohme LLC NCT05067283

Набира участници Фаза 2

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

Myelofibrosis

The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.

Начало: 16.12.2021 Край: 28.02.2030 Възраст: от 18 г. Лечение

Australia, Brazil, France +4 Takeda NCT05037760

Набира участници

Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

Motor Neuron Disease / Amyotrophic Lateral Sclerosis

A two-arm, individual participant randomised controlled, assessor-blinded trial in 7 MND care centres across Australia will be undertaken.

Начало: 15.12.2021 Край: 28.02.2028 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT05136222

Набира участници

RFC1 Natural History Study

Ataxia

This international, multi-center, multi-modal and prospective observational study aims to determine the phenotypic spectrum and the natural progression of the RFC1 repeat expansion disease, and to seek and validate digital, imaging, and molecular biomarkers that aid in diagnosis and serve as outcome measures in future clinical trials of this novel, but frequent ataxia with late adult-onset.

Начало: 14.12.2021 Край: 01.12.2026 Възраст: от 18 г.

Australia, Brazil, France +4 Prof. Dr. Matthis Synofzik NCT05177809

1 … 185 186 187 188 189 … 222